Atorvaliq is a drug owned by Cmp Development Llc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 07, 2037. Details of Atorvaliq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11654106 | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | Active |
| US11925704 | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | Active |
| US11369567 | Aqueous suspension suitable for oral administration |
Jun, 2037
(12 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Atorvaliq's patents.
Latest Legal Activities on Atorvaliq's Patents
Given below is the list of recent legal activities going on the following patents of Atorvaliq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 12 Mar, 2024 | US11925704 |
| Patent eGrant Notification | 12 Mar, 2024 | US11925704 |
| Recordation of Patent eGrant | 12 Mar, 2024 | US11925704 |
| Patent Issue Date Used in PTA Calculation Critical | 12 Mar, 2024 | US11925704 |
| Email Notification Critical | 12 Mar, 2024 | US11925704 |
| Recordation of Patent Grant Mailed Critical | 12 Mar, 2024 | US11925704 |
| Email Notification Critical | 22 Feb, 2024 | US11925704 |
| Issue Notification Mailed Critical | 21 Feb, 2024 | US11925704 |
| Application Is Considered Ready for Issue Critical | 08 Feb, 2024 | US11925704 |
| Dispatch to FDC | 08 Feb, 2024 | US11925704 |
US patents provide insights into the exclusivity only within the United States, but Atorvaliq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Atorvaliq's family patents as well as insights into ongoing legal events on those patents.
Atorvaliq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Atorvaliq's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 07, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Atorvaliq Generic API suppliers:
Atorvastatin Calcium is the generic name for the brand Atorvaliq. 31 different companies have already filed for the generic of Atorvaliq, with Zydus Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Atorvaliq's generic
Alternative Brands for Atorvaliq
Atorvaliq which is used for reducing LDL-C levels in patients with homozygous familial hypercholesterolemia., has several other brand drugs using the same active ingredient (Atorvastatin Calcium). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Atorvastatin Calcium, Atorvaliq's active ingredient. Check the complete list of approved generic manufacturers for Atorvaliq
About Atorvaliq
Atorvaliq is a drug owned by Cmp Development Llc. It is used for reducing LDL-C levels in patients with homozygous familial hypercholesterolemia. Atorvaliq uses Atorvastatin Calcium as an active ingredient. Atorvaliq was launched by Cmp Dev Llc in 2023.
Approval Date:
Atorvaliq was approved by FDA for market use on 01 February, 2023.
Active Ingredient:
Atorvaliq uses Atorvastatin Calcium as the active ingredient. Check out other Drugs and Companies using Atorvastatin Calcium ingredient
Treatment:
Atorvaliq is used for reducing LDL-C levels in patients with homozygous familial hypercholesterolemia.
Dosage:
Atorvaliq is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG/5ML | SUSPENSION | Prescription | ORAL |